Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A10–3 Health Care Costs Associated with Histoplasma Disease

 

% with Care

Cost per Unit

Units per Case

Form of treatment

Flu-like illness

 

(single state)

100%

$50

2.0

physician a

 

50%

$150

1.0

medication b, diagnostic b

Pneumonitis: outpatient only

 

(single state)

100%

$350

1.0

outpatient treatment 2 physician b, medication b, diagnostic b

Pneumonitis: w/ inpatient

 

inpatient care

100%

$5,000

1.0

hospitalization

outpatient care

100%

$350

1.0

outpatient treatment (same as above)

Disseminated histoplasmosis

 

disseminated intravascular coagulation, splenomegaly, hepatomegaly, fever

50%

$5,000

1.0

hospitalization

outpatient only

50%

$1,250

1.0

outpatient—3 months (8 physician b, 3 medicaion c)

recovery

50%

$1,250

1.0

outpatient—3 months

Chronic pulmonary

 

symptomatic (untreated, initial treatment)

40%

$5,000

1.0

hospitalization

outpatient treatment

100%

$1,250

3.0

outpatient (same as for disseminated disease)

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a H. capsulatum vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $300,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $600,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement